phosphorus has been researched along with lanthanum carbonate in 75 studies
| Studies (phosphorus) | Trials (phosphorus) | Recent Studies (post-2010) (phosphorus) | Studies (lanthanum carbonate) | Trials (lanthanum carbonate) | Recent Studies (post-2010) (lanthanum carbonate) |
|---|---|---|---|---|---|
| 48,074 | 1,126 | 17,139 | 390 | 87 | 218 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (32.00) | 29.6817 |
| 2010's | 47 (62.67) | 24.3611 |
| 2020's | 4 (5.33) | 2.80 |
| Authors | Studies |
|---|---|
| Amor, J; Palma, A | 1 |
| Behets, GJ; D'Haese, PC; De Broe, ME; Verberckmoes, SC | 1 |
| Behets, GJ; Bouillon, R; D'Haese, PC; Damment, SJ; Dams, G; De Broe, ME; Vercauteren, SR | 1 |
| Finn, WF; Hladik, G; Joy, MS | 1 |
| Finn, WF; Joy, MS | 1 |
| Finch, J; Liapis, H; Slatopolsky, E | 1 |
| Denton, J; Freemont, AJ; Hoyland, JA | 1 |
| Brooks, T; Candiani, C; Hudson, JQ; Joy, MS; Kshirsagar, A | 1 |
| Finn, WF | 1 |
| D'Haese, PC; De Broe, ME; Freemont, T; Gelev, S; Gill, M; Jones, C; Masin-Spasovska, J; Sikole, A; Spasovski, GB; Webster, I | 1 |
| Negri, AL | 1 |
| Anger, M; Fishbane, S; Martin, KJ; Mehrotra, R; Sprague, SM; Zeig, S | 1 |
| Barnett, ME; Hutchison, AJ; Krause, R; Kwan, JT; Siami, GA | 1 |
| Confer, S; Malluche, HH; Mawad, H; Monier-Faugere, MC; Pratt, RD; Siami, GA; Smith, M; Swanepoel, C; Wang, GH | 1 |
| Rodríguez Portillo, M | 1 |
| Torregrosa Prats, V | 1 |
| Fernandez Giraldez, E; Sánchez González, MC; Valdivielso Revilla, JM | 1 |
| Valdivieso, JM | 1 |
| Abboud, H; Dauphin, M; Finn, W; Qiu, P; Sprague, SM; Zhang, P | 1 |
| Alonso, M; Andrés, E; Ballarín, J; Bover, J; Canal, C; Farré, N; Olaya, MT; Quílez, B | 1 |
| Hutchison, AJ; Mohammed, I | 1 |
| Craig, JC; Elder, GJ; Navaneethan, SD; Palmer, SC; Strippoli, GF | 1 |
| Krause, R; Nath, SD; Pratt, RD; Ross, EA; Sprague, SM; Zhang, P | 1 |
| Alonso Alvarez, MA; Díez Ojeda, B; Medrano Martínez, S | 1 |
| Grand-Pierre, AE; Larusso, J; Li, Q; Uitto, J | 1 |
| Noto, L | 1 |
| Álvarez-Ude, F; Arenas, MD; Gil, MT; Malek, T; Moledous, A; Reig-Ferrer, A | 1 |
| Damment, S; Lorenzo, V; Rodriguez, M; Secker, R; Shen, V | 1 |
| Anattiwong, P; Arruda, JA; How, PP; Lau, AH; Mason, DL | 1 |
| Arisaka, H; Nakaoka, A; Shigematsu, T; Tokumoto, A | 1 |
| Galán, A; Gonzalez-Casaus, ML; Gonzalez-Parra, E; Martinez-Calero, A; Navas, V; Ortiz, A; Rodriguez, M | 1 |
| Fujii, H; Fujimori, A; Fukagawa, M; Goto, S; Hasegawa, H; Kamae, I; Kim, JI; Komaba, H; Moriwaki, K; Nishi, S; Nishioka, M; Shibuya, K; Shin, J; Taniguchi, M; Yoshiya, K | 1 |
| Ketteler, M; Petermann, AT | 1 |
| Matalon, A; Michelis, MF; Vemuri, N | 1 |
| Brunner-Ziegler, S; Fröschl, B; Hiebinger, C; Zsifkovits, J | 1 |
| Moe, SM; Moorthi, RN | 1 |
| Benner, D; Burgess, M; Colson, C; Krishnan, M; Mayne, TJ; Poole, L; Ricketts, K; Smyth, M; Wilson, S | 1 |
| Dennis, K; Pennick, M; Poole, L; Smyth, M | 1 |
| Delport, PC; Dribusch, U; Gropp, JM; Schmidt, BH; van der Staay, FJ | 1 |
| Flanigan, M; Haynes, WG; Kalil, RS; Stanford, W | 1 |
| Chiyotanda, S; Fujimoto, S; Fukudome, K; Kitamura, K; Sato, Y; Toida, T; Yamada, K | 1 |
| Hasegawa, Y; Kamo, Y; Kikuchi, N; Matsuda, E; Sekino, H; Sekino, M; Takeuchi, K | 1 |
| Ando, R; Chida, Y; Shinoda, T; Suzuki, T; Tagawa, H; Takagi, M; Tanaka, Y; Yamasaki, M | 1 |
| Adachi, T; Ando, R; Fukami, K; Hazama, T; Kaida, Y; Kohno, K; Kusumoto, T; Manabe, R; Nakayama, Y; Okuda, S; Sakai, K; Ueda, S; Wada, Y; Yamagishi, S | 1 |
| Inaba, M; Ito, A; Nitta, K; Otsubo, S; Satoh, S; Tanaka, M; Tominaga, Y; Yajima, A | 1 |
| Hirose, M; Ishida, Y; Izumiya, Y; Ota, S | 1 |
| Kabaya, T; Mitsuhashi, T; Miyajima, S; Nitta, K; Ogawa, T; Ohba, T; Otsuka, K; Shizuku, J; Takahashi, M; Takahashi, N; Yamashita, T | 1 |
| Bierhals, AJ; Cheng, SC; Dávila-Román, VG; de las Fuentes, L; Dietzen, DJ; Hruska, KA; Ross, W; Rothstein, M; Seifert, ME; Windus, D | 1 |
| Kimura, K; Oishi, D; Sakurada, T; Shibagaki, Y; Yasuda, T | 1 |
| Kong, XL; Li, WB; Wang, ZS; Wei, Y | 1 |
| Galani, VJ; Prajapati, VA; Shah, PR | 1 |
| Copley, JB; Keddad, K; Preston, P; Prié, D; Ureña-Torres, P; Wan, H; Wilde, P | 1 |
| Ando, R; Chida, Y; Inagaki, Y; Inoue, A; Ishida, Y; Iwamoto, S; Kikuchi, K; Kimura, H; Ohnishi, T; Ohtsuka, M; Tachibana, K; Takayama, M; Yama, S; Yamada, K | 1 |
| Hara, K; Kishi, Y; Kurosawa, N; Obara, Y; Takada, D; Yamashiro, H | 1 |
| Hida, M; Hyodo, T; Ishii, D; Iwamura, M; Kawakami, J; Kurata, Y; Mikami, N; Wakai, H; Yoshida, K | 1 |
| Fujimoto, T; Furuhashi, M; Harada, M; Kamiya, E; Kato, A; Maruyama, S; Okamoto, M; Suzuki, H; Takita, T; Tamiya, R; Tukada, A | 1 |
| Haruhara, K; Kamejima, S; Kanzaki, G; Mafune, H; Manabe, M; Mashiko, H; Okamoto, H; Yokoo, T | 1 |
| Kumagai, J; Mukai, I; Takahashi, N; Tsuchiya, S; Yoshizawa, T | 1 |
| Iida, A; Matsuo, A; Matsushita, M; Miyamoto, K; Tanimoto, M | 1 |
| Li, L; Sun, QL; Wang, R; Yu, XS; Zhai, CJ; Zhang, LT; Zhou, AY | 1 |
| Sun, J; Wang, R; Yang, XW; Zhai, CJ | 1 |
| Fukagawa, M; Hida, M; Kakuta, T; Komaba, H; Suga, T; Suzuki, H | 1 |
| Buemi, M; Coppolino, G; Fuiano, G; Lacquaniti, A; Leonello, G; Lucisano, S; Rivoli, L; Santoro, D; Villari, A; Villari, I | 1 |
| Kawashima, S; Minakuchi, J; Nagai, K; Tsuchida, K; Yokota, N | 1 |
| Benner, D; Bross, R; Jing, J; Kalantar-Zadeh, K; Koontz Parsons, T; Kopple, JD; Kovesdy, CP; Lee, ML; Mehrotra, R; Rhee, CM; St-Jules, DE; Tortorici, AR; You, AS | 1 |
| Kobayashi, M; Takeda, H; Tatemichi, S; Yaguchi, A | 1 |
| St Peter, WL; Wazny, LD; Weinhandl, ED | 1 |
| Li, H; Lu, X; Wang, F; Wang, S; Xiong, R; Zhang, J | 1 |
| Fukagawa, M; Hida, M; Kakuta, T; Komaba, H; Suga, T; Wada, T | 1 |
| Kinoshita, O; Motomura, N; Ono, M; Yamauchi, H | 1 |
| Chen, YQ; Miao, YY; Xia, M; Xu, CM; Zhu, HQ | 1 |
| Behets, GJ; Blust, R; D'Haese, PC; Finsterle, K; Lamberts, L; Mubiana, KV; Traill, N | 1 |
| Fujii, H; Goto, S; Kono, K; Nishi, S; Watanabe, K | 1 |
| Wang, L; Yang, J; Zhang, X | 1 |
| Chen, Y; Cui, X; Jiang, S; Liu, L; Tang, X | 1 |
15 review(s) available for phosphorus and lanthanum carbonate
| Article | Year |
|---|---|
[Management of hyperphosphoremia].
Topics: Calcinosis; Calcium; Case Management; Chelating Agents; Chelation Therapy; Epoxy Compounds; Humans; Hyperparathyroidism, Secondary; Iron; Kidney Failure, Chronic; Lanthanum; Phosphorus; Polyamines; Polyethylenes; Sevelamer | 2003 |
Lanthanum carbonate: a new phosphate binder.
Topics: Bone and Bones; Buffers; Clinical Trials as Topic; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus; Phosphorus Metabolism Disorders | 2004 |
Lanthanum carbonate.
Topics: Animals; Chronic Disease; Clinical Trials as Topic; Humans; Kidney Diseases; Lanthanum; Phosphorus; Treatment Outcome | 2006 |
[K-DOQI guidelines for calcium and phosphorus metabolism in chronic kidney disease: outcomes, compliance and new drugs for treatment].
Topics: Calcium; Cinacalcet; Humans; Kidney Failure, Chronic; Lanthanum; Naphthalenes; Phosphorus; Polyamines; Practice Guidelines as Topic; Sevelamer; Treatment Outcome | 2007 |
[Introduction to lanthanum carbonate: pharmacology, safety and tolerability].
Topics: Animals; Bone and Bones; Chelating Agents; Chelation Therapy; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hyperphosphatemia; Intestinal Absorption; Kidney Failure, Chronic; Lanthanum; Liver; Nervous System; Phosphorus; Rats; Tissue Distribution | 2008 |
[Lanthanum carbonate in clinical practice].
Topics: Administration, Oral; Chelating Agents; Chelation Therapy; Clinical Trials as Topic; Gastrointestinal Diseases; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Liver; Phosphorus; Tablets | 2008 |
[Control of phosphorus and treatment with vitamin D in chronic kidney disease prior to the start of dialysis].
Topics: Calcifediol; Calcinosis; Calcitriol; Cardiovascular Diseases; Chronic Disease; Chronic Kidney Disease-Mineral and Bone Disorder; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Phosphorus; Polyamines; Prevalence; Renal Dialysis; Sevelamer; Vitamin D; Vitamin D Deficiency | 2008 |
[Experimental advances in mineral metabolism].
Topics: Animals; Calcinosis; Calcium; Cardiovascular Diseases; Chelating Agents; Chelation Therapy; Chronic Disease; Drug Evaluation, Preclinical; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Intestinal Absorption; Kidney; Kidney Diseases; Lanthanum; Phosphorus; Sodium-Phosphate Cotransporter Proteins | 2008 |
Update on the treatment of chronic kidney disease-mineral and bone disorder.
Topics: Aluminum Compounds; Calcinosis; Calcium Carbonate; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Diet, Protein-Restricted; Dietetics; Humans; Kidney Failure, Chronic; Lanthanum; Naphthalenes; Nephrology; Nutrition Assessment; Nutritive Value; Parathyroidectomy; Patient Care Team; Patient Education as Topic; Phosphorus; Polyamines; Practice Guidelines as Topic; Sevelamer; Vitamin D | 2009 |
Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
Topics: Acetates; Administration, Oral; Aluminum Hydroxide; Calcium Carbonate; Calcium Compounds; Cardiovascular Diseases; Chelating Agents; Drug Monitoring; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Magnesium; Nephrology; Patient Education as Topic; Phosphorus; Polyamines; Practice Guidelines as Topic; Renal Dialysis; Sevelamer; Treatment Outcome | 2009 |
Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Topics: Acetates; Biomarkers; Bone Density Conservation Agents; Calcium; Calcium Carbonate; Calcium Compounds; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Hypercalcemia; Hyperphosphatemia; Lanthanum; Parathyroid Hormone; Phosphates; Phosphorus; Polyamines; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Research Design; Sevelamer | 2009 |
Effect of lanthanum carbonate versus calcium-based phosphate binders in dialysis patients: a meta-analysis.
Topics: Calcium; Calcium Phosphates; Chelating Agents; Dialysis Solutions; Humans; Hypercalcemia; Lanthanum; Parathyroid Hormone; Phosphorus; Renal Dialysis | 2014 |
Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis.
Topics: Bone Density; Calcium; Calcium Carbonate; Chelating Agents; Humans; Hypercalcemia; Lanthanum; Parathyroid Hormone; Phosphorus; Radiography; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Vascular Calcification | 2015 |
Effect of Lanthanum Carbonate on All-Cause Mortality in Patients Receiving Maintenance Hemodialysis: a Meta-Analysis of Randomized Controlled Trials.
Topics: Calcium; Cardiovascular Diseases; Humans; Hyperphosphatemia; Lanthanum; Mortality; Parathyroid Hormone; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis | 2018 |
Effects of lanthanum carbonate and calcium carbonate on cardiovascular calcification in hemodialysis patients: A systematic review and meta-analysis.
Topics: Calcium; Calcium Carbonate; Chelating Agents; Fibroblast Growth Factor-23; Humans; Lanthanum; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis | 2022 |
28 trial(s) available for phosphorus and lanthanum carbonate
| Article | Year |
|---|---|
Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.
Topics: Calcium; Double-Blind Method; Drug Tolerance; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Safety | 2004 |
A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
Topics: Adolescent; Adult; Aged; Calcium; Dose-Response Relationship, Drug; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Phosphorus Metabolism Disorders; Renal Dialysis; Time Factors; Treatment Outcome | 2005 |
The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Calcitriol; Calcium; Calcium Carbonate; Chronic Kidney Disease-Mineral and Bone Disorder; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Phosphorus; Renal Dialysis; Treatment Outcome | 2005 |
Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.
Topics: Female; Follow-Up Studies; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus; Renal Dialysis; Treatment Outcome | 2006 |
Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up.
Topics: Aged; Alkaline Phosphatase; Biomarkers; Calcifediol; Calcitriol; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Female; Follow-Up Studies; Humans; Ilium; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Phosphorus; Renal Dialysis; Treatment Outcome | 2006 |
Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Drug Administration Schedule; Female; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Male; Middle Aged; Patient Satisfaction; Phosphorus; Renal Dialysis; Tablets; Time Factors; Treatment Outcome; United States | 2008 |
Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus; Treatment Outcome | 2008 |
Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years.
Topics: Adult; Analysis of Variance; Biomarkers; Bone Remodeling; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Female; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis; Treatment Outcome | 2008 |
Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Double-Blind Method; Female; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Calcium; Chelating Agents; Cross-Over Studies; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Polyamines; Renal Dialysis; Sevelamer; Treatment Outcome | 2009 |
Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia.
Topics: Adult; Aged; Bone and Bones; Chronic Kidney Disease-Mineral and Bone Disorder; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Prospective Studies; Renal Dialysis; Young Adult | 2011 |
Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Biomarkers; Cardiovascular Diseases; Chelating Agents; Cost-Benefit Analysis; Drug Costs; Female; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Models, Economic; Phosphorus; Quality-Adjusted Life Years; Renal Dialysis; Time Factors; Treatment Outcome; Young Adult | 2011 |
Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study.
Topics: Administration, Oral; Adult; Aged; Attitude of Health Personnel; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Patient Satisfaction; Phosphates; Phosphorus; Physicians; Tablets; Treatment Outcome | 2011 |
Results of a pilot program to improve phosphorus outcomes in hemodialysis patients.
Topics: Aged; Bone and Bones; Calcium; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Minerals; Nutritional Status; Parathyroid Hormone; Phosphorus; Pilot Projects; Prospective Studies; Renal Dialysis; Serum Albumin | 2012 |
Lanthanum carbonate reduces urine phosphorus excretion: evidence of high-capacity phosphate binding.
Topics: Administration, Oral; Adolescent; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Phosphorus; Phosphorus Compounds; Phosphorus, Dietary; Reference Values; Single-Blind Method; Young Adult | 2012 |
Tolerability and efficacy of the intestinal phosphate binder Lantharenol® in cats.
Topics: Animal Feed; Animals; Cats; Dose-Response Relationship, Drug; Feces; Food Additives; Lanthanum; Phosphorus; Phosphorus, Dietary | 2012 |
Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study.
Topics: Aged; Biomarkers; Brachial Artery; Calcium; Chelating Agents; Chronic Disease; Coronary Artery Disease; Disease Progression; Endothelium, Vascular; Humans; Iowa; Kidney Diseases; Lanthanum; Middle Aged; Phosphorus; Pilot Projects; Polyamines; Prospective Studies; Renal Dialysis; Sevelamer; Time Factors; Treatment Outcome; Vascular Calcification; Vasodilation | 2012 |
Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.
Topics: Acid Phosphatase; Aged; Alkaline Phosphatase; Analysis of Variance; Calcium; Calcium Carbonate; Chelating Agents; Chi-Square Distribution; Cross-Over Studies; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hypercalcemia; Hyperphosphatemia; Isoenzymes; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Tartrate-Resistant Acid Phosphatase; Vitamin D | 2012 |
Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients.
Topics: Adult; Aged; Calcium; Calcium Carbonate; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypercalcemia; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus; Polyamines; Renal Dialysis; Sevelamer; Vitamin D | 2013 |
Improvement of MBD parameters in dialysis patients by a switch to, and combined use of lanthanum carbonate: Josai Dialysis Forum collaborative study.
Topics: Bone Diseases; Calcium; Calcium Carbonate; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Polyamines; Renal Dialysis; Sevelamer; Vitamin D | 2013 |
Effects of switching from calcium carbonate to lanthanum carbonate on bone mineral metabolism in hemodialysis patients.
Topics: Aged; Bone and Bones; Calcium; Calcium Carbonate; Female; Follow-Up Studies; Humans; Inflammation; Interleukin-6; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Prospective Studies; Real-Time Polymerase Chain Reaction; Renal Dialysis; RNA, Messenger; Vitamin D | 2013 |
Additional reduction in serum phosphorus levels by pulverized lanthanum carbonate chewable in hemodialysis patients.
Topics: Administration, Oral; Aged; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Mastication; Middle Aged; Phosphorus; Renal Dialysis | 2013 |
Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Diabetes Complications; Double-Blind Method; Feasibility Studies; Female; Homeostasis; Humans; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus; Phosphorus, Dietary; Pilot Projects; Renal Insufficiency, Chronic; Risk Factors; Treatment Outcome; Vascular Stiffness | 2013 |
Effect of calcium carbonate combined with calcitonin on hypercalcemia in hemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; Calcitonin; Calcium; Calcium Carbonate; Drug Therapy, Combination; Female; Humans; Hypercalcemia; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Young Adult | 2014 |
Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Lanthanum; Male; Middle Aged; Phosphorus; Placebo Effect; Reference Values; Renal Insufficiency, Chronic; Treatment Outcome | 2014 |
Multicenter study on the long-term (3-year) efficacy of lanthanum carbonate in dialysis patients.
Topics: Aged; Calcium; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Time Factors; Treatment Outcome | 2014 |
Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
Topics: Aged; Calcium; Calcium Carbonate; Chelating Agents; Dose-Response Relationship, Drug; Female; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Polyamines; Renal Dialysis; Sevelamer; Time Factors; Treatment Outcome | 2014 |
Effect of high-protein meals during hemodialysis combined with lanthanum carbonate in hypoalbuminemic dialysis patients: findings from the FrEDI randomized controlled trial.
Topics: Bone Diseases; Dietary Proteins; Female; Humans; Hypoalbuminemia; Lanthanum; Male; Middle Aged; Phosphorus; Renal Dialysis | 2017 |
32 other study(ies) available for phosphorus and lanthanum carbonate
| Article | Year |
|---|---|
Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?
Topics: Alkaline Phosphatase; Animals; Bone and Bones; Bone Diseases; Bone Remodeling; Calcium; Creatinine; Eating; Kidney Failure, Chronic; Lanthanum; Male; Osteoblasts; Osteocalcin; Parathyroid Hormone; Phosphates; Phosphorus; Rats; Rats, Wistar; Vitamin D | 2004 |
Progressive accumulation of lanthanum in the liver of normal and uremic rats.
Topics: Animal Feed; Animals; Creatinine; Female; Femur; Hyperparathyroidism, Secondary; Kidney; Kidney Failure, Chronic; Lanthanum; Liver; Phosphorus; Rats; Rats, Sprague-Dawley; Uremia | 2005 |
[Radiology image of lanthanum carbonate].
Topics: Abdominal Pain; Artifacts; Chelating Agents; Chelation Therapy; Colon; Diabetic Nephropathies; Diagnosis, Differential; Diverticulitis, Colonic; Diverticulosis, Colonic; Fever; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Renal Dialysis; Tomography, X-Ray Computed | 2010 |
Magnesium carbonate-containing phosphate binder prevents connective tissue mineralization in Abcc6(-/-) mice-potential for treatment of pseudoxanthoma elasticum.
Topics: Animals; ATP-Binding Cassette Transporters; Calcification, Physiologic; Calcium; Connective Tissue; Diet; Femur; Lanthanum; Magnesium; Mice; Mice, Inbred C57BL; Minerals; Multidrug Resistance-Associated Proteins; Phosphates; Phosphorus; Pseudoxanthoma Elasticum; Tomography, X-Ray Computed; Vibrissae | 2009 |
Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
Topics: Acetates; Aged; Aged, 80 and over; Calcium Carbonate; Calcium Compounds; Chelating Agents; Humans; Kidney Failure, Chronic; Lanthanum; Middle Aged; New York; Nutritional Status; Phosphates; Phosphorus; Polyamines; Renal Dialysis; Retrospective Studies; Serum Albumin; Sevelamer; Treatment Outcome | 2011 |
[Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control].
Topics: Acetates; Aged; Aluminum Hydroxide; Calcium Compounds; Chelating Agents; Chelation Therapy; Cohort Studies; Cross-Sectional Studies; Dyspepsia; Female; Health Knowledge, Attitudes, Practice; Humans; Lanthanum; Male; Middle Aged; Patient Compliance; Patient Preference; Phosphorus; Polyamines; Renal Dialysis; Sevelamer; Surveys and Questionnaires; Tablets; Taste | 2010 |
Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure.
Topics: Animals; Bone Diseases; Calcification, Physiologic; Calcium; Kidney Failure, Chronic; Lanthanum; Male; Minerals; Phosphorus; Rats; Rats, Wistar | 2011 |
Phosphate-binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients.
Topics: Administration, Oral; Female; Humans; Hyperparathyroidism, Secondary; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus; Renal Dialysis; Tablets | 2011 |
Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients.
Topics: Aged; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Lanthanum; Longitudinal Studies; Male; Phosphorus; Prognosis; Prospective Studies | 2011 |
Phosphate and FGF23 in early CKD: on how to tackle an invisible foe.
Topics: Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Kidney Failure, Chronic; Lanthanum; Male; Phosphorus | 2011 |
Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
Topics: Adult; Aged; Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cost Savings; Health Care Costs; Hemodialysis Solutions; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Parathyroid Hormone; Phosphorus; Polyamines; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Technology Assessment, Biomedical | 2011 |
CKD-mineral and bone disorder: core curriculum 2011.
Topics: Bone Diseases; Calcinosis; Calciphylaxis; Calcitriol; Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney; Kidney Failure, Chronic; Kidney Tubules; Lanthanum; Parathyroid Hormone; Parathyroidectomy; Phosphorus; Polyamines; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Vitamin D | 2011 |
Impact of lanthanum carbonate on cortical bone in dialysis patients with adynamic bone disease.
Topics: Aged; Bone and Bones; Bone Diseases; Dose-Response Relationship, Drug; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic | 2013 |
Effects of switch from sevelamer hydrochloride to lanthanum carbonate on serum K and bone metabolic turnover.
Topics: Adult; Aged; Alkaline Phosphatase; Bicarbonates; Bone and Bones; Bone Remodeling; Calcium; Cholesterol; Dose-Response Relationship, Drug; Female; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Polyamines; Potassium; Renal Dialysis; Sevelamer | 2013 |
Efficacy of oral powder compared with chewable tablets for lanthanum carbonate administration in hemodialysis patients.
Topics: Administration, Oral; Aged; Calcium; Female; Humans; Lanthanum; Male; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Tablets; Treatment Outcome | 2013 |
A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Topics: Acetates; Adult; Biomarkers; Calcium; Calcium Carbonate; Calcium Compounds; Chelating Agents; Female; Humans; Hypercalcemia; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Polyamines; Renal Dialysis; Retrospective Studies; Sevelamer; Time Factors; Treatment Outcome | 2014 |
Increase in the dosage amount of vitamin D3 preparations by switching from calcium carbonate to lanthanum carbonate.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Calcium; Calcium Carbonate; Cholecalciferol; Dose-Response Relationship, Drug; Female; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Prognosis; Renal Dialysis; Retrospective Studies | 2014 |
Effects of change in the formulation of lanthanum carbonate on laboratory parameters.
Topics: Aged; Calcium; Chemistry, Pharmaceutical; Female; Geriatric Assessment; Humans; Lanthanum; Male; Middle Aged; Nutrition Assessment; Parathyroid Hormone; Patient Preference; Phosphorus; Renal Dialysis; Retrospective Studies; Serum Albumin; Tablets | 2014 |
Is granular formulation of lanthanum carbonate more effective than chewable tablets?
Topics: Adult; Aged; Chemistry, Pharmaceutical; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Phosphorus; Renal Dialysis; Retrospective Studies; Tablets | 2014 |
Questionnaire survey and serum phosphorus levels in maintenance hemodialysis patients switching lanthanum carbonate formulation from chewable tablets to granules.
Topics: Adult; Aged; Aged, 80 and over; Chemistry, Pharmaceutical; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Medication Adherence; Middle Aged; Patient Preference; Phosphorus; Renal Dialysis; Surveys and Questionnaires; Tablets | 2014 |
The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats.
Topics: Animals; Calcium Carbonate; Ferric Compounds; Intestinal Absorption; Lanthanum; Male; Phosphorus; Rats; Rats, Sprague-Dawley | 2014 |
Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia.
Topics: Aged; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Renal Dialysis; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Sevalamer Hydrochloride, Sevelamer Carbonate and Lanthanum Carbonate: In Vitro and In Vivo Effects on Gastric Environment.
Topics: Aged; Carbon Dioxide; Chelating Agents; Drug Liberation; Drug Tolerance; Female; Gastric Acidity Determination; Humans; Hydrogen-Ion Concentration; Lanthanum; Male; Phosphorus; Proton Pump Inhibitors; Renal Dialysis; Sevelamer; Stomach | 2015 |
Impact of Lanthanum Carbonate on Prognosis of Chronic Hemodialysis Patients: A Retrospective Cohort Study (Kawashima Study).
Topics: Aged; Cardiovascular Diseases; Chelating Agents; Cohort Studies; Disease Progression; Female; Humans; Lanthanum; Male; Middle Aged; Phosphorus; Prognosis; Proportional Hazards Models; Renal Dialysis; Retrospective Studies; Treatment Outcome; Vascular Calcification | 2016 |
PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure.
Topics: Adenine; Animals; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Models, Animal; Dose-Response Relationship, Drug; Ferric Compounds; Kidney Failure, Chronic; Lanthanum; Male; Parathyroid Hormone; Phosphorus; Rats; Sevelamer; Treatment Outcome | 2017 |
Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.
Topics: Calcium; Chelating Agents; Drug and Narcotic Control; Health Care Costs; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Medicare Part D; Needs Assessment; Phosphorus; Renal Dialysis; Sevelamer; United States | 2018 |
Nutritional status and survival of maintenance hemodialysis patients receiving lanthanum carbonate.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Nutritional Status; Phosphates; Phosphorus; Propensity Score; Renal Dialysis; Treatment Outcome | 2019 |
Lanthanum carbonate, a phosphate binder, inhibits calcification of implanted aortic allografts in a rat model.
Topics: Allografts; Animals; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Blood Vessel Prosthesis; Calcium; Calcium Carbonate; Lanthanum; Male; Models, Animal; Phosphorus; Rats; Rats, Inbred BN; Rats, Inbred Lew; Transplantation, Homologous; Vascular Calcification | 2019 |
Relationship between Gut Microbiota and Phosphorus Metabolism in Hemodialysis Patients: A Preliminary Exploration.
Topics: Child; Female; Gastrointestinal Microbiome; Humans; Lanthanum; Male; Middle Aged; Phosphorus; Prospective Studies; Renal Dialysis; Risk Factors; Uremia | 2018 |
Use of lanthanum for water treatment A matter of concern?
Topics: Animals; Bentonite; Eutrophication; Lanthanum; Liver; Phosphorus; Rats; Water Purification | 2020 |
Comparison of the effects of lanthanum carbonate and calcium carbonate on the progression of cardiac valvular calcification after initiation of hemodialysis.
Topics: Aged; Aged, 80 and over; Biomarkers; Calcinosis; Calcium Carbonate; Chelating Agents; Disease Progression; Female; Heart Valve Diseases; Humans; Kidney Diseases; Lanthanum; Male; Middle Aged; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Time Factors; Treatment Outcome | 2020 |
Effect of low-dose lanthanum carbonate on calcium and phosphorus metabolism in Asian Patients with end-stage renal disease, maintenance hemodialysis and hyperphosphatemia.
Topics: Calcium; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Phosphorus; Renal Dialysis | 2022 |